BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36867344)

  • 1. Loss of p53 Concurrent with RAS and TERT Activation Induces Glioma Formation.
    Gong M; Fan X; Yu H; Niu W; Sun S; Wang H; Chen X
    Mol Neurobiol; 2023 Jun; 60(6):3452-3463. PubMed ID: 36867344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner.
    Muñoz DM; Tung T; Agnihotri S; Singh S; Guha A; Zadeh G; Hawkins C
    Glia; 2013 Nov; 61(11):1862-72. PubMed ID: 24038521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 Palmitoylation Mediated by ZDHHC5 in p53-Mutant Glioma Drives Malignant Development and Progression.
    Chen X; Ma H; Wang Z; Zhang S; Yang H; Fang Z
    Cancer Res; 2017 Sep; 77(18):4998-5010. PubMed ID: 28775165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of cancerous neural stem cells forming glial tumor by oncogenic stimulation.
    Lee JS; Lee HJ; Moon BH; Song SH; Lee MO; Shim SH; Kim HS; Lee MC; Kwon JT; Fornace AJ; Kim SU; Cha HJ
    Stem Cell Rev Rep; 2012 Jun; 8(2):532-45. PubMed ID: 21755312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
    Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
    Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells.
    Bartesaghi S; Graziano V; Galavotti S; Henriquez NV; Betts J; Saxena J; Minieri V; A D; Karlsson A; Martins LM; Capasso M; Nicotera P; Brandner S; De Laurenzi V; Salomoni P
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1059-64. PubMed ID: 25583481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process.
    Galvao RP; Kasina A; McNeill RS; Harbin JE; Foreman O; Verhaak RG; Nishiyama A; Miller CR; Zong H
    Proc Natl Acad Sci U S A; 2014 Oct; 111(40):E4214-23. PubMed ID: 25246577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.
    Ding H; Shannon P; Lau N; Wu X; Roncari L; Baldwin RL; Takebayashi H; Nagy A; Gutmann DH; Guha A
    Cancer Res; 2003 Mar; 63(5):1106-13. PubMed ID: 12615729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma.
    Abel TW; Clark C; Bierie B; Chytil A; Aakre M; Gorska A; Moses HL
    Mol Cancer Res; 2009 May; 7(5):645-53. PubMed ID: 19435821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.
    Lee JS; Park JR; Kwon OS; Lee TH; Nakano I; Miyoshi H; Chun KH; Park MJ; Lee HJ; Kim SU; Cha HJ
    Neuro Oncol; 2015 Jan; 17(1):95-106. PubMed ID: 25096191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche.
    Zou Y; Niu W; Qin S; Downes M; Burns DK; Zhang CL
    Mol Cell Biol; 2012 Dec; 32(23):4811-20. PubMed ID: 23028043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
    BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
    You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
    CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
    Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
    Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
    Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
    Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
    Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
    Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse induced glioma-initiating cell models and therapeutic targets.
    Kondo T
    Anticancer Agents Med Chem; 2010 Jul; 10(6):471-80. PubMed ID: 20879984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
    Sonoda Y; Ozawa T; Hirose Y; Aldape KD; McMahon M; Berger MS; Pieper RO
    Cancer Res; 2001 Jul; 61(13):4956-60. PubMed ID: 11431323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-κB-mediated miR-650 plays oncogenic roles and activates AKT/ERK/NF-κB pathways by targeting RERG in glioma cells.
    Jin S; Li X; Dai Y; Li C; Wang D
    Cell Oncol (Dordr); 2020 Dec; 43(6):1035-1048. PubMed ID: 32986146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.